Figure 2. Kaplan-Meier curves for overall survival.
Overall survival is shown for assessable patients randomly allocated to erlotinib plus bevacizumab (bevacizumab group) or erlotinib plus placebo (control group). Thep value for overall survival is based on a stratified log-rank test; stratification factors were Eastern Cooperative Oncology Group performance status, smoking history, and sex.